gms | German Medical Science

35. Internationaler Kongress der Deutschen Ophthalmochirurgie (DOC)

15.06. - 17.06.2023, Nürnberg

Dietary intervention with a targeted micronutrient formulation reduces floaters and enhances vision-related quality of life and visual function of patients suffering from vitreous floaters (B, I, P – Ebiga Vision)

Meeting Abstract

Suche in Medline nach

  • John Nolan - Nutrition Research Centre Ireland, School of Health Sciences, Waterford, Irland

35. Internationaler Kongress der Deutschen Ophthalmochirurgie (DOC). Nürnberg, 15.-17.06.2023. Düsseldorf: German Medical Science GMS Publishing House; 2023. DocFP 1.5

doi: 10.3205/23doc005, urn:nbn:de:0183-23doc0059

Veröffentlicht: 13. Juni 2023

© 2023 Nolan.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Purpose: Floaters are regarded as a visual nuisance that impact negatively on the quality of life of its sufferers. This study was conducted to investigate the impact of supplementation with a targeted micronutrient formulation on the visual discomfort associated with vitreous degeneration.

Methods: In this clinical trial, 61 patients with symptomatic vitreous floaters were randomized to consume daily, the active supplement consisting of 125 mg L-lysine, 40 mg vitamin C, 26.3 mg Vitis vinifera extract, 5 mg zinc, and 100 mg Citrus aurantium or placebo for 6 months. Change in visual discomfort from floaters, assessed with the Floater Disturbance Questionnaire, was the primary outcome measure. Secondary outcome measures included best-corrected visual acuity, letter contrast sensitivity, photopic functional contrast sensitivity with positive and negative contrast polarity, and quantitative vitreous opacity areas.

Results: After supplementation, the active group reported a significant decrease in their visual discomfort from floaters (P<0.001), whereas the placebo group had no significant change in their visual discomfort (P=0.416). At 6 months, there was a significant decrease in vitreous opacity areas in the active group (P<0.001) and an insignificant increase in vitreous opacity areas in the placebo group (P=0.081). Also, there was a significant improvement in photopic functional contrast sensitivity with positive contrast polarity in the active group after supplementation (P=0.047).

Conclusions: The findings of this study indicate improvements in vision-related quality of life and visual function of patients suffering from vitreous floaters after supplementation with a formulation of antioxidative and antiglycation micronutrients. Notably, these improvements were confirmed by the decrease in vitreous opacity areas in the active group.